Tivic Health Systems Rebrands as Valion Bio, Reflecting Completed Transformation into a Late-Stage Biopharmaceutical Company with Government-Backed Asset and Potential Multiple Revenue Stream Model

Rhea-AI Summary

Valion Bio (formerly Tivic Health Systems; Nasdaq: TIVC → VBIO) completed a strategic transformation into a late-stage biopharmaceutical company, effective April 28, 2026. The company centers on lead candidate Entolimod, a TLR5 agonist with FDA Fast Track and Orphan Drug designations and Animal Rule development for ARS.

Valion also owns CDMO Velocity Bioworks (acquired Dec 2025 for ~$16.3M), completed a 200-fold Entolimod scale-up at 50L, and is engaging BARDA and other agencies on SNS procurement that could represent a non-dilutive, potentially nine-figure revenue event.

Positive

• Lead asset Entolimod has FDA Fast Track and Orphan Drug designations
• Potential non-dilutive, nine-figure SNS procurement opportunity if contract secured
• Acquired Velocity Bioworks for $16.3M providing domestic CDMO capability
• Completed a 200-fold Entolimod manufacturing scale-up at 50L meeting specs

Negative

• No signed SNS procurement contract yet; revenue remains contingent on government awards
• Entolimod approval path relies on the Animal Rule, requiring regulatory acceptance of animal data
• Commercial revenue from Velocity depends on achieving full utilization and third-party CDMO demand
• Clinical oncology program target (Phase IIb readiness in 2026) remains to be executed and funded

Market Context

This announcement detailed a completed pivot into a late-stage biopharmaceutical model built around ...

Analysis

This announcement detailed a completed pivot into a late-stage biopharmaceutical model built around Entolimod, which has accumulated over $140 million in development investment and targets both Acute Radiation Syndrome and a neutropenia market above $22 billion. It also emphasized the Velocity Bioworks CDMO, acquired for about $16.3 million, as a potential independent revenue source. Investors may track BARDA and SNS procurement discussions, oncology trial initiation in 2026, and utilization of the 200-fold manufacturing scale-up.

Key Figures

Development history: over 15 years Cumulative investment: $140 million Neutropenia market size: $22 billion +5 more

8 metrics

Development history over 15 years Cumulative development investment in Entolimod

Cumulative investment $140 million Cumulative development investment in lead asset Entolimod

Neutropenia market size $22 billion Global neutropenia treatment market current size

Neutropenia market outlook $30 billion Projected global neutropenia market by early 2030s

Trial timing 2026 Target start for physician-sponsored neutropenia trials

Phase target Phase IIb Readiness objective for chemotherapy-induced neutropenia program

CDMO acquisition price $16.3 million Purchase price for Velocity Bioworks in December 2025

Manufacturing scale-up 200-fold; 50-liter 200-fold Entolimod scale-up using 50-liter fermentation

Key Terms

toll-like receptor 5, fast track, orphan drug, animal rule, +4 more

8 terms

toll-like receptor 5 medical

"Entolimod™, is a novel Toll-like receptor 5 (TLR5) agonist with a"

Toll-like receptor 5 (TLR5) is a protein on certain immune cells that acts like a security sensor, detecting a specific component of bacterial tails and triggering an inflammation and immune response. Investors care because drugs or vaccines that activate or block TLR5 can change how the body fights infections or cancer, serving as therapeutic targets or vaccine ingredients; progress or setbacks in TLR5-focused research can materially affect the value and prospects of biotech firms.

fast track regulatory

"Entolimod has received FDA Fast Track and Orphan Drug designations"

A fast track designation is a regulatory label that speeds up the review and communication between a drug developer and regulators for treatments addressing serious illnesses or unmet medical needs. For investors, it matters because it can shorten development time and reduce regulatory delays—like getting a VIP lane at the airport—raising the chance of earlier market access and potential revenue, though it does not guarantee approval.

orphan drug regulatory

"Entolimod has received FDA Fast Track and Orphan Drug designations"

A drug designated for an orphan disease is a medicine developed to treat a rare condition that affects only a small number of people. Regulators often give these drugs special incentives—such as reduced costs, faster review, and temporary exclusive selling rights—to encourage development, which matters to investors because those incentives can make a small market financially viable and reduce competition, much like a temporary patent on a niche product.

animal rule regulatory

"advanced under the FDA's Animal Rule pathway — a regulatory framework"

A regulatory pathway that allows safety and effectiveness of drugs or vaccines to be judged primarily from well-controlled animal studies when human trials would be unethical or impossible, such as for treatments against rare, lethal exposures. It matters to investors because approval via this route can speed a product to market for urgent or niche needs but carries extra scientific and regulatory risk—think of it as accepting a high-quality dress rehearsal instead of a live show, with requirements for strong animal models and often additional post-approval obligations.

strategic national stockpile regulatory

"regarding Entolimod's inclusion in the U.S. Strategic National Stockpile (SNS)"

A strategic national stockpile is a government-held reserve of critical medical supplies, medicines, vaccines and equipment kept to respond quickly to public health emergencies. For investors, it matters because government purchases, replenishment schedules and stockpile policies can create sudden demand, long-term contracts or regulatory priorities that directly affect makers, distributors and suppliers of those goods—think of it as a national emergency pantry that can drive corporate revenue and risk.

cdmo technical

"Valion Bio's wholly owned CDMO subsidiary, Velocity Bioworks, was acquired"

A contract development and manufacturing organization (CDMO) is a company that provides specialized services to help develop and produce pharmaceutical products for other businesses. Think of it as a contract factory that takes a company's recipe and makes the product on their behalf. For investors, CDMOs are important because they support the growth of pharmaceutical companies and can be key partners in bringing new medicines to market.

chemotherapy-induced neutropenia medical

"clinical trials in chemotherapy-induced neutropenia in 2026, with Phase IIb"

A drop in infection-fighting white blood cells caused by chemotherapy, which leaves patients more vulnerable to infections and may require antibiotics, hospital care, or delays in cancer treatment. For investors, this matters because the frequency and severity of these episodes affect drug safety profiles, clinical trial outcomes, healthcare costs, and demand for supportive medicines or devices—similar to how a weakened defense force changes how a city must respond and allocate resources.

phase ii regulatory

"neutropenia in 2026, with Phase IIb readiness as the objective."

Phase II is the mid-stage clinical trial where a potential drug or medical treatment is tested in a larger group of patients to see if it works and to help determine the best dose and common side effects. For investors, Phase II results matter because they give the first meaningful evidence about effectiveness and safety—like a road test that shows whether a product has real promise before a much bigger, costly final trial and potential regulatory approval.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Ticker Symbol to Change from TIVC to VBIO Effective April 28, 2026; Company Advancing Entolimod™ Toward BARDA Funding and Strategic National Stockpile Procurement While Velocity Bioworks CDMO Builds Independent Revenue Base

SAN ANTONIO, April 23, 2026 /PRNewswire/ -- Tivic Health Systems, Inc. (Nasdaq: TIVC) today announced it is changing its corporate name to Valion Bio, Inc. and its Nasdaq ticker symbol from TIVC to VBIO, effective at market open on Tuesday, April 28, 2026. The CUSIP number for the company's common stock will remain unchanged.

The rebrand is not merely cosmetic. It reflects the completion of a fundamental strategic transformation — the deliberate unwinding of a consumer medical device business and its replacement with a focused late-stage biopharmaceutical platform anchored by a government-priority asset with over 15 years and more than $140 million in cumulative development investment, and supported by a wholly owned biomanufacturing subsidiary.

A Differentiated Asset at the Intersection of National Preparedness and Oncology

Valion Bio's lead drug candidate, Entolimod™, is a novel Toll-like receptor 5 (TLR5) agonist with a differentiated, dual-utility profile. As a medical countermeasure for Acute Radiation Syndrome (ARS), Entolimod has received FDA Fast Track and Orphan Drug designations and is being advanced under the FDA's Animal Rule pathway — a regulatory framework that enables approval based on animal efficacy data when human trials are not feasible or ethical, substantially reducing clinical execution risk. The company is actively engaged with BARDA, DTRA, NIAID, and allied government agencies regarding Entolimod's inclusion in the U.S. Strategic National Stockpile (SNS), where a procurement contract — if secured — would represent a non-dilutive, potentially nine-figure revenue event.

Critically, Entolimod's mechanism — cytoprotection of bone marrow and gastrointestinal epithelial tissue through NF-κB signaling — positions it for parallel development in oncology supportive care. The global neutropenia treatment market exceeds $22 billion and is projected to approach $30 billion by the early 2030s. Valion Bio is targeting physician-sponsored clinical trials in chemotherapy-induced neutropenia in 2026, with Phase IIb readiness as the objective. Entolasta™, a next-generation TLR5 agonist, provides additional pipeline depth and intellectual property extension across both indications.

"The Valion Bio name reflects the company we have become. We have a late-stage asset with validated biology, regulatory designations, a clear government procurement pathway, and a world-class manufacturing operation under one roof. This is a different company than the one that existed 18 months ago — and the new name should make that unmistakable to every investor, partner, and government stakeholder we engage."
— Michael K. Handley, Chief Executive Officer, Valion Bio

Handley, who previously served as CEO of Statera Biopharma, where he led the advancement of Entolimod, brings direct institutional knowledge of the asset, its regulatory history, and its government agency relationships. His appointment as CEO of Valion Bio in March 2026 consolidated scientific, commercial, and operational leadership of the program under a single decision-maker with a proven track record in biologic drug development at scale.

Velocity Bioworks: Manufacturing as a Strategic and Financial Asset

Valion Bio's wholly owned CDMO subsidiary, Velocity Bioworks, was acquired in December 2025 for approximately $16.3 million and represents a core pillar of the company's strategy — not a peripheral asset. Velocity Bioworks provides the company with domestic, controlled manufacturing capability for Entolimod, enabling supply chain security that is increasingly a prerequisite for government procurement partnerships. The subsidiary also recently completed a 200-fold manufacturing scale-up of Entolimod using 50-liter fermentation — on time, within budget, and meeting all purity and potency specifications.

Beyond its internal role, Velocity Bioworks operates as a standalone CDMO with the ability to serve  third-party early-stage biotech clients, targeting the historically underserved Phase I and Phase II biologics manufacturing gap. At full utilization, management believes Velocity Bioworks has the potential to evolve into a self-sustaining, cash flow-positive operation — providing the company a path to non-dilutive commercial revenue independent of the drug development timeline.

Strategic Positioning and Macro Tailwinds

Valion Bio is deliberately headquartered in San Antonio, Texas — proximity to the DoD biodefense ecosystem, including Brooke Army Medical Center, is not coincidental. The company's ARS countermeasure program sits at the intersection of several converging macro forces: a renewed federal focus on domestic biomanufacturing, accelerating global demand for national preparedness infrastructure following heightened nuclear threat awareness, and a bipartisan mandate to rebuild and modernize the Strategic National Stockpile. Allied government agencies are independently evaluating Entolimod for their own national stockpiling programs, creating a potential multi-jurisdictional procurement opportunity.

About Valion Bio (Tivic Health Systems, Inc.)

Valion Bio is a late-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation. The company's lead candidate, Entolimod™, is a TLR5 agonist with over 15 years of development history, FDA Fast Track and Orphan Drug designations, and active engagement with U.S. government agencies for potential Strategic National Stockpile inclusion. The company also advances Entolasta™, a next-generation TLR5 agonist, and targets the neutropenia oncology supportive care market. Velocity Bioworks, Valion Bio's wholly owned CDMO subsidiary, supports internal manufacturing and services third-party biotech clients. For more information, visit https://ir.tivichealth.com 

Forward-Looking Statements

This press release may contain "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim, "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Valion Bio, Inc.'s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including as a result of the company's interactions with and guidance from the FDA and other regulatory authorities; the continued interest of BARDA and other U.S. government agencies in Entolimod™; the ability of the company to achieve the expected benefits from the acquisition of development and manufacturing assets within expected time frames or at all; changes to the company's relationship with its partners; failure to obtain FDA or similar clearances or approvals and noncompliance with FDA or similar regulations, including related to the Animal Rule; the company's future development of Entolimod or Entolasta; changes to the company's business strategy; timing and success of pre-clinical and clinical trials and study results; regulatory requirements and pathways for approval; the company's ability to successfully commercialize its product candidates in the future; changes in the markets and industries in which the company does business; consummation of any strategic transactions; the company's need for, and ability to secure when needed, additional working capital; the company's ability to maintain its Nasdaq listing; and changes in tariffs, inflation, legal, regulatory, political and economic risks. Accordingly, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of risks and uncertainties relevant to the company, and other important factors, see Valion Bio's filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 30, 2026, under the heading "Risk Factors", as well as the company's subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and the company undertakes no duty to update such information except as required by applicable law.

Investor Contact
ir@tivichealth.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/tivic-health-systems-rebrands-as-valion-bio-reflecting-completed-transformation-into-a-late-stage-biopharmaceutical-company-with-government-backed-asset-and-potential-multiple-revenue-stream-model-302752163.html

SOURCE Tivic Health Systems, Inc.

FAQ

When does Tivic Health Systems change its Nasdaq ticker from TIVC to VBIO?

The ticker changes at market open on April 28, 2026. According to the company, the CUSIP for common stock remains unchanged and the rebrand reflects a strategic shift.

What is Entolimod and what regulatory designations does VBIO report for it?

Entolimod is a TLR5 agonist advanced for ARS and oncology supportive care. According to the company, it holds FDA Fast Track and Orphan Drug designations and is being pursued under the Animal Rule pathway.

How could Entolimod generate revenue through the U.S. Strategic National Stockpile (SNS)?

A procurement contract for SNS would be a non-dilutive, potentially nine-figure revenue event. According to the company, engagements with BARDA and allied agencies are ongoing but no contract is yet secured.

What role does Velocity Bioworks play in Valion Bio's strategy and finances?

Velocity Bioworks is a wholly owned CDMO acquired for $16.3M to supply Entolimod and serve third parties. According to the company, full utilization could lead to a self-sustaining cash flow-positive operation.

What are Valion Bio's near-term clinical plans for Entolimod in oncology supportive care?

Valion Bio targets physician-sponsored trials in chemotherapy-induced neutropenia in 2026, aiming for Phase IIb readiness. According to the company, this parallels ARS development to pursue supportive-care indications.